Claudia Venturi

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Simona Soverini, Caterina De Benedittis, Kateřina Machová Poláková et al. · Blood · 2013 · 162 citations · Full text

Medicine, Molecular Biology, Molecular Medicine +14

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Simona Soverini, Caterina De Benedittis, Cristina Papayannidis et al. · Cancer · 2013 · 143 citations · Full text

Medicine, Hematology, Oncology +16

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Helen White, Matthew Salmon, Francesco Albano et al. · Leukemia · 2022 · 38 citations · Full text

Medicine, Hematology, Oncology +14

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients

Stefania Trino, Ilaria Iacobucci, Daniela Erriquez et al. · Oncotarget · 2016 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

Ilaria Iacobucci, Andrea Ghelli Luserna di Rorà, Maria Vittoria Verga Falzacappa et al. · Journal of Hematology & Oncology · 2015 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17